NCT06560424|Recruiting
Loading search results
Sponsor study identifier
observational
10,000
1 country
1
Study Start
September 18, 2024
Actual (reported)Primary Completion
December 31, 2050
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2050
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The purpose of the Cardiovascular and Metabolic Sciences Biorepository is to collect and store information and biospecimens (blood, urine, stool, and heart tissue) from patients with and without cardiovascular and metabolic diseases to create a readily available biorepository of samples and related medical health information to expedite future research into the causes and consequences of cardiovascular and metabolic diseases.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2050
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 13, 2024
Actual (reported)August 19, 2024
Actual (reported)September 18, 2024
Actual (reported)December 31, 2050
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2050
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Number of samples enrolled per year
Establish a biorepository of samples (blood, urine, stool, and heart tissue) and related medical health information to support future investigation into cardiovascular and metabolic diseases.
Yearly through study completion (approximately 30 years)
Persons who have a diagnosis of a cardiovascular or metabolic disease. Examples of cardiovascular diseases are: heart failure, arrhythmias, high cholesterol, coronary artery disease, heart attack, and stroke. Examples of metabolic diseases are: diabetes, metabolic syndrome, and hemochromatosis.
Persons without a personal diagnosis of any cardiovascular or metabolic disease but with a family history in a first-degree relative of one of those diseases.
No personal or family (first-degree relative) history of cardiovascular or metabolic diseases.
We will enroll persons with diagnosed cardiovascular or metabolic disease(s), persons with a family history of cardiovascular and/or metabolic disease(s), and persons without known cardiovascular or metabolic disease(s). The targeted number of participants to be enrolled is indefinite.
Cleveland Clinic Main Campus
Cleveland, Ohio, 44195, United States
Blood (plasma, serum, whole blood, and/or PBMCs), urine, stool, and/or heart tissue samples.
W. H. Wilson Tang, MD
The Cleveland Clinic
First Submitted
August 13, 2024
First Posted
August 19, 2024
Study Start
September 18, 2024
Actual (reported)Primary Completion
December 31, 2050
EstimatedThe Effects of Healthy Diets With Plant Oils on Heart and Metabolic Health
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2050
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
June 25, 2026
Record last verified: 2026-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: